PeptiNox Quarterly Trust Report: Q1 2026 Vendor Performance Review

PeptiNox is committed to transparency — not only about individual vendor assessments but about the overall state of the research peptide market. This Quarterly Trust Report presents aggregated findings from our Q1 2026 evaluation cycle, covering January through March 2026. Individual vendor identities are not disclosed in this report; our focus is on market-wide trends, quality patterns, and actionable insights for the research community.

Executive Summary

Q1 2026 demonstrated continued improvement in overall market quality, with average trust scores among evaluated vendors rising for the third consecutive quarter. However, the gap between top-tier and entry-level vendors has widened, and PeptiNox's independent testing identified persistent quality concerns among a subset of the market.

Key metrics:

• -Vendors evaluated in Q1 2026: 38
• -New vendor evaluations: 7
• -Re-evaluations of existing vendors: 31
• -Average trust score (all evaluated vendors): 8.2
• -Median trust score: 8.4
• -Score range: 5.8 - 9.6

Market Quality Overview

Trust Score Distribution

The Q1 2026 trust score distribution across evaluated vendors:

Elite tier (9.0-10.0): 6 vendors (16%) — These vendors demonstrate excellence across all evaluation domains. They maintain comprehensive analytical documentation, pass independent testing with minimal discrepancies, operate with full business transparency, and deliver consistently positive customer experiences.

Verified tier (8.0-8.9): 18 vendors (47%) — The largest segment. These vendors meet PeptiNox verification standards with satisfactory performance across all evaluation domains. Minor improvement opportunities exist but do not compromise overall quality assurance.

Pending tier (7.0-7.9): 8 vendors (21%) — These vendors show potential but have not met full verification standards in one or more evaluation domains. Specific improvement recommendations have been provided, and they will be re-evaluated upon addressing identified gaps.

Unverified tier (below 7.0): 6 vendors (16%) — These vendors have not met minimum verification standards. Concerns range from incomplete analytical documentation to significant discrepancies in independent testing to business legitimacy questions.

Quarter-over-Quarter Trends

Comparing Q1 2026 to Q4 2025:

• -Average trust score increased from 8.0 to 8.2 (+0.2)
• -The number of vendors in the Elite tier increased from 5 to 6
• -The number of vendors in the Unverified tier decreased from 8 to 6
• -Three vendors improved from Pending to Verified status
• -Two vendors were downgraded from Verified to Pending status
• -One vendor exited the market during the quarter

The upward trend in average trust scores reflects genuine market quality improvement driven by vendor investment in analytical infrastructure, documentation practices, and operational quality.

Independent Testing Results

PeptiNox conducted independent analytical testing on 52 products from 28 vendors during Q1 2026. Testing included HPLC purity analysis and mass spectrometry identity confirmation.

Purity Concordance

Overall purity concordance: 87% of tested products showed independent purity values within 2% of vendor-stated claims. This represents an improvement from 83% in Q4 2025.

Breakdown by tier:

• -Elite tier vendors: 96% concordance within 2%
• -Verified tier vendors: 89% concordance within 2%
• -Pending tier vendors: 78% concordance within 2%
• -Unverified tier vendors: 62% concordance within 2%

The correlation between trust score tier and purity concordance validates PeptiNox's scoring methodology — higher-scored vendors demonstrably deliver more accurate quality claims.

Identity Confirmation

Overall identity confirmation rate: 97% of tested products were confirmed as the correct compound by mass spectrometry. Three products (from two different vendors) showed identity concerns — molecular weights inconsistent with the labeled peptide.

Both vendors with identity concerns were in the Unverified tier. Their trust scores were adjusted with Critical Failure modifiers, and enhanced monitoring has been initiated.

Notable Findings

Finding 1: Oxidation as a persistent impurity. Methionine-containing peptides showed higher rates of oxidative impurities across all vendor tiers. This appears to be a market-wide challenge related to handling and storage sensitivity rather than a vendor-specific quality issue.

Finding 2: Improving COA quality. The percentage of vendors providing chromatograms with COAs increased from 72% in Q4 2025 to 78% in Q1 2026. Mass spectrometry data availability increased from 58% to 64%.

Finding 3: Net peptide content reporting. Only 34% of evaluated vendors report net peptide content in addition to HPLC purity. This metric is important for accurate research dosing and remains an area where market practice lags behind best standards.

Documentation Quality Assessment

COA Completeness

PeptiNox evaluated COA completeness across all evaluated vendors using a standardized checklist of expected data elements:

| Data Element | Percentage of Vendors Including |

|---|---|

| Purity percentage | 100% |

| HPLC chromatogram | 78% |

| Mass spectrometry data | 64% |

| Batch/lot number | 91% |

| Peptide sequence | 88% |

| Molecular weight | 85% |

| Method parameters | 62% |

| Net peptide content | 34% |

| Residual solvent data | 22% |

Assessment: COA completeness is improving but remains inconsistent across the market. The gap between best-practice documentation (100% of data elements) and market average documentation remains significant.

COA Authenticity

PeptiNox's forensic analysis of COAs in Q1 2026 identified:

• -2 cases of suspected COA duplication (identical chromatograms across different batch numbers)
• -1 case of a COA format inconsistent with the stated testing laboratory
• -0 cases of confirmed COA fabrication

The low rate of authenticity concerns among evaluated vendors reflects the deterrent effect of systematic verification. Vendors aware of PeptiNox scrutiny are less likely to submit questionable documentation.

Customer Experience Data

Aggregated Feedback Metrics

PeptiNox aggregated customer feedback data from multiple sources for Q1 2026:

• -Total feedback data points collected: 1,247
• -Average satisfaction score: 4.2/5.0
• -Most common positive themes: Product quality, shipping speed, analytical documentation
• -Most common negative themes: Payment processing difficulties, limited product availability, customer service response times

Complaint Analysis

Complaint patterns identified during Q1 2026:

• -Shipping delays: 38% of complaints — primarily related to carrier issues rather than vendor processing delays
• -Payment processing: 24% of complaints — reflecting ongoing industry challenges with payment processors
• -Product availability: 18% of complaints — popular peptides periodically out of stock
• -Quality concerns: 12% of complaints — the most significant category for PeptiNox monitoring
• -Other: 8% — miscellaneous issues including website functionality and communication

The relatively low percentage of quality-related complaints (12%) among evaluated vendors indicates that the vendors in our evaluation program are generally delivering acceptable product quality. However, PeptiNox notes that quality complaints may be underreported — researchers may not always report quality issues publicly.

Vendor Movement

Score Increases

Eight vendors showed trust score increases in Q1 2026 re-evaluations. Common factors contributing to score increases:

• -Addition of mass spectrometry data to COAs
• -Improved purity concordance in independent testing
• -Enhanced shipping practices (cold chain improvements)
• -Increased customer feedback volume with positive trends

Score Decreases

Four vendors showed trust score decreases. Common factors:

• -Purity discrepancies in independent testing (2 vendors)
• -COA documentation regression (1 vendor)
• -Significant customer complaint pattern (1 vendor)

New Evaluations

Seven new vendors completed initial evaluation during Q1 2026:

• -3 achieved Verified status (scores 8.0-8.7)
• -3 received Pending status (scores 7.2-7.8)
• -1 received Unverified status (score 6.4)

The new vendor cohort shows higher initial quality than previous quarters, suggesting that market standards are rising and new entrants are aware of quality expectations.

Recommendations for Researchers

Based on Q1 2026 findings, PeptiNox offers the following recommendations:

• -Purchase from Verified or Elite tier vendors for critical research applications. The correlation between trust tier and independent testing concordance is strong and consistent.

• -Request MS data even if not included in standard COAs. The 64% availability rate means over a third of vendors do not routinely include identity confirmation data.

• -Be aware of oxidation sensitivity for methionine-containing peptides. Request fresh synthesis or verify storage conditions when ordering these compounds.

• -Maintain payment flexibility. Payment processing challenges affect even top-tier vendors. Having alternative payment methods available prevents disruption to research supply chains.

• -Report quality concerns. The 12% complaint rate for quality issues likely underrepresents actual quality variations. Reporting to PeptiNox improves our market monitoring capabilities.

Looking Ahead: Q2 2026

PeptiNox's Q2 2026 evaluation cycle will focus on:

• -Re-evaluation of all Pending tier vendors with updated improvement assessments
• -Expanded independent testing coverage across more products per vendor
• -Enhanced cold chain assessment protocols for summer shipping conditions
• -Continued onboarding of new vendor evaluations

The research peptide market continues its quality maturation trajectory. PeptiNox is committed to providing the independent verification and market transparency that supports this positive evolution.

*This report is published for research community information purposes. All products referenced are for research purposes only. Not for human consumption.*